Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab plus pyrotinib in plasma HER2-amplified advanced breast cancer identified by digital PCR
ChiCTR2100049619Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and pyrotinib in breast cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Response rate, Progression-free survival and 1 more. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
trastuzumabpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100049619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049619.